Table 2.
Ongoing Clinical Trials with Polatuzumab in Patients with B-Cell NHL
| NCT# (Study Name) | Phase | NHL Subtype(s) | Treatments | Site(s) | Recruiting (Yes/No) |
|---|---|---|---|---|---|
| NCT04231877 | 1 | Previously untreated aggressive B-cell + PMBCL | DA-EPCH-R + pola | US | No |
| NCT03274492 (POLARIX) | 3 | Previously untreated DLBCL | Pola-R-CHP vs R-CHOP | US | Fully recruited |
| NCT03671018 (GO40516) | 1b/2 | R/R FL | Mosunetuzumab (M) + pola vs R-CHOP, R-CVP, or BG | US | Yes |
| R/R DLBCL | Pola-BR vs M monotherapy vs M + pola | ||||
| NCT04236141 | 3 | R/R DLBCL | Pola-BR vs BR | China | No |
| NCT04182204 (POLARGO) | 3 | R/R DLBCL | Pola-R-GemOx vs R-GemOx | International | Yes |
| NCT02600897 | 1b/2 | R/R FL R/R DLBCL |
Pola-lenalidomide + obinutuzumab (FL) or rituximab (DLBCL) | International | Yes |
| NCT02611323 | 1b/2 | R/R FL R/R DLBCL |
Pola-venetoclax + obinutuzumab (FL) or rituximab (DLBCL) | International | Yes |
| NCT03533283 | 1b | R/R B-cell NHL | RO7082859 (CD20xCD3 bispecific) + pola, or RO7082859 + atezolizumab | Europe | Yes |
| NCT03677141 | 1b | R/R NHL | M-CHOP, M-CHP-pola | International | Yes |
| 2 | Previously untreated DLBCL | M-CHOP or M-CHP-pola vs pola-R-CHP | |||
| NCT02729896 | 1b/2 | R/R DLBCL R/R FL |
Pola-atezolizumab + obinutuzumab (FL) or rituximab (DLBCL) | International | No |
Abbreviations: BG, obinutuzumab and bendamustine; BR, bendamustine and rituximab; CHP, cyclophosphamide, doxorubicin and prednisone; DA-EPCH-R, dose-adjusted rituximab, etoposide, cyclophosphamide, and doxorubicin; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; M, mosunetuzumab (CD20xCD3 bispecific antibody); NHL, non-Hodgkin lymphoma; Pola, polatuzumab; PMBCL, primary mediastinal large B-cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine and prednisone; R-GemOx, rituximab, gemcitabine, and oxaliplatin; R/R, relapsed/refractory.